BioCentury
ARTICLE | Clinical News

GS 504: Completed interim analysis of its Phase II/III trial

June 20, 1994 7:00 AM UTC

Gilead Sciences Inc. (GILD), Foster City, Calif. Product: GS 504, nucleotide analog Indication: Retinitis caused by cytomegalovirus infection in AIDS Status: Completed interim analysis of its Phase I...